Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities

References

[1] El-khoueiry AB,Yau T.Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017;389:2492-502 PMCID:PMC7539326

[2] Zhu AX,Edeline J.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.Lancet Oncol2018;19:940-52

[3] Yau T,Kim TY.Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the checkmate 040 randomized clinical trial.JAMA Oncol2020;6:e204564 PMCID:PMC7530824

[4] Cheng AL,Ikeda M.Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.J Hepatol2022;76:862-73

[5] Lee MS,Hsu C.Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.Lancet Oncol2020;21:808-20

[6] Zhu AX,Abbas AR.Abstract CT044: genomic correlates of clinical benefits from atezolizumab combined with bevacizumab vs. atezolizumab alone in patients with advanced hepatocellular carcinoma (HCC).Cancer Res2020;80:CT044-CT044

[7] Zhu AX,de Galarreta MR.Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.Nat Med2022;28:1599-611

[8] Feng Z,Liu Y.The immune microenvironment and progression of immunotherapy and combination therapeutic strategies for hepatocellular carcinoma.Hepatoma Res2021;7:3

[9] Bonilla CM,Fu J.Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.Hepatoma Res2020;6:68 PMCID:PMC7597818

[10] Pfister D,Pinyol R.NASH limits anti-tumour surveillance in immunotherapy-treated HCC.Nature2021;592:450-6 PMCID:PMC8046670

[11] Peng Y,Yu J.The paradox of immunotherapy in NASH-HCC.Signal Transduct Target Ther2021;6:228 PMCID:PMC8192918

[12] Younossi Z,Ong JP.Global Nonalcoholic Steatohepatitis CouncilNonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.Clin Gastroenterol Hepatol2019;17:748-755.e3

[13] Lindblad KE,Lujambio A.Tumor-intrinsic mechanisms regulating immune exclusion in liver cancers.Front Immunol2021;12:642958 PMCID:PMC8107356

[14] Murai H,Maesaka K.Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.Hepatology2022;Online ahead of print: